Solid Tumor, Miscellaneous research hub

Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells

This study is looking at a drug called pemigatinib for solid cancers that have a specific change (alteration) in a gene called FGFR. It's for people whose cancer has come back or spread, and it aims to see if pemigatinib can help shrink or control these cancers.